Equitable HRR testing in mPC care

As HRR testing becomes increasingly central to personalized treatment in mPC care, how do we ensure it’s implemented equitably and effectively across all clinical settings? Arun Azad discusses (Peter MacCallum Cancer Centre and University of Melbourne, Australia) the real‑world challenges that limit widespread adoption of HRR testing in mPC. View video. View transcript.

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information

Name

Email address

Specialty

By providing your email address, you are opting in to receive our monthly newsletter.

Opt-in: By selecting this box, I consent to receiving marketing communications and information about Medthority's resources by email.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.

Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.